EC Gastroenterology and Digestive System

Case Report Volume 10 Issue 6 - 2023

Intestinal Microbiota Transplantation and Clostridiodes difficile. A Relevant Case

Álvaro Zamudio Tiburcio1*, Héctor Bermúdez Ruiz2, Silverio Alonso López3, Pedro Antonio Reyes López4 and Martín Julián Carrillo5

1Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico

2Endoscopy Service, Oncology Hospital, National Medical Center, XXI Century, Mexican Social Security. Institute, Hospital Trinidad, Mexico City, Mexico

3Department of Urologist, Chairman Medical Specialties Naples in Mexico City, Mexico

4Immunologist, Rheumatologist, National Institute of Cardiology “I. Chávez”, Mexico City, Mexico

5Critical Medicine. Hospital Trinidad, Mexico City, Mexico

*Corresponding Author: Álvaro Zamudio Tiburcio, Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico.
Received: June 19, 2023; Published: June 27, 2023

After delving into numerous articles and having our own history of successful intestinal microbiota transplantation (IMT), we were fortunate that a new patient was referred, with pseudomembranous colitis; on this occasion, Clostridiodes difficile covered the entire colon.

The patient, 75 years old, and the history that her husband had died of sepsis caused by the same bacterium, and a series of co-morbidities, which are explained in their corresponding place.

The first transplant was performed one week after the onset of diarrhea, due to failure with antibiotic therapy, using fecal microbiota of less than 8 hours of preparation, and given the severe findings, we point out the need for a new colon exploration, in not more than 72 hours. This was carried out a week later, where, surprisingly, we observed that the enormous amount of C. difficile had disappeared, leaving only minimal lesions in the rectum, for which reason we performed a second IMT, following the total cure of the pathological process.

Keywords: Intestinal Microbiota Transplantation (IMT); Clostridiodes difficile (CD); Intestinal Microbiota (IM); Probiotics, Prebiotics and Symbiotics (BIOT)

  1. Faming Z., et al. “Should We Standardize the 1,700-Year-Old Fecal Microbiota Transplantation?” American Journal of Gastroenterology11 (2012): 1733.
  2. Eiseman B., et al. “Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis”. Surgery5 (1958): 854-859.
  3. Rowan K. “Poop transplant may combat bacterial infection”. Live Sciences 20 (2012): 10-20.
  4. Borody TJ., et al. “Fecal microbiota transplantation. Indications, methods, evidence and future direction”. Current Gastroenterology 15 (2013): 337.
  5. Borody TJ., et al. “Fecal microbiota transplantation (FMT) in multiple sclerosis (MS)”. The American Journal of Gastroenterology 10 (2011): S352.
  6. Zheng L., et al. “Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives”. World Journal of Gastroenterology23 (2022): 2546-2560.
  7. Gupta S., et al. “Fecal microbiota transplantation: in perspective”. Therapeutic Advances in Gastroenterology - SAGE Journals2 (2016): 229-239.
  8. Biazo M and Deidda G. “Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases”. Journal of Clinical Medicine14 (2022): 4119.
  9. Hamamah S., et al. “Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols”. Frontiers in Medicine Gastroenterology 9 (2022).
  10. Wang X., et al. “Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity”. Molecules19 (2021): 6076.
  11. Park SY and Seo GS. “Fecal Microbiota Transplantation: Is It Safe?” Clinical Endoscopy2 (2021): 157-160.
  12. Hourigan SK., et al. “Updates and Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children”. Journal of Pediatric Gastroenterology and Nutrition4 (2021): 430-432.
  13. Ross CN and Reveles KR. “Feasibility of fecal microbiota transplantation via oral gavage to safely alter gut microbiome composition in marmosets”. American Journal of Primatology12 (2020): e23196.
  14. Kim KO and Gluck M. “Fecal Microbiota Transplantation: An Update on Clinical Practice”. Clinical Endoscopy2 (2019): 137-143.
  15. Rusha Pal., et al. “Probiotics: insights and new opportunities for Clostridioides difficile intervention”. Critical Reviews in Microbiology3 (2023): 414-434.
  16. Na X and Kelly C. “Probiotics in Clostridium difficile Infection”. Journal of Clinical Gastroenterology (2011): S154-S148.
  17. Madoff SE., et al. “Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials”. Anaerobe 61(2020): 102098.
  18. Kondepudi KK., et al. “A novel multi-strain probiotic and synbiotic supplement for prevention of Clostridium difficile infection in a murine model”. Medical Microbiology and Immunology10 (2014): 552-558.
  19. Akter S., et al. “Potential Health-Promoting Benefits of Paraprobiotics, Inactivated Probiotic Cells”. Journal of Microbiology and Biotechnology4 (2020): 477-481.
  20. Adèle Rakotonirina., et al. “Fecal microbiota transplantation: a review on current formulations in Clostridioides difficile infection and future outlooks”. Expert Opinion on Biological Therapy7 (2022): 929-944.

Álvaro Zamudio Tiburcio., et al. "Intestinal Microbiota Transplantation and Clostridiodes difficile. A Relevant Case". EC Gastroenterology and Digestive System  10.6 (2023): 01-06.